2024 Step Therapy Protocols

Imperial Senior Value (HMO C-SNP) 005

Imperial Traditional (HMO) 007

Imperial Dual Plan (HMO D-SNP) 011

Imperial Dynamic Plan (HMO) 012

Imperial Strong (HMO) 014



STEP THERAPY PROGRAMS

How do I request an exception to the Imperial Health Plan of California (HMO) (HMO SNP)?

You can ask Imperial Health Plan of California (HMO) (HMO SNP) to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover your drug even if it is not on our formulary.
- You can ask us to waive coverage restrictions or limits on your drug. For example, being required to first try certain drugs to treat your medical condition before we will cover another drug for that condition or generic version of a drug instead of the original brand name drug.
- You can ask us to provide a higher level of coverage for your drug. If your drug is contained in our non-preferred tier, you can ask us to cover it at the cost-sharing amount that applies to drugs in the preferred tier instead. This would lower the amount you must pay for your drug. Please note, if we grant your request to cover a drug that is not on our formulary, you may not ask us to provide a higher level of coverage for the drug. "Also, you may not ask us to provide a higher level of coverage for drugs that are in the specialty tier."

Generally, Imperial Health Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower-tiered drug or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, tiering or utilization restriction exception. When you are requesting a formulary, tiering or utilization restriction exception you should submit a statement from your physician supporting your request. Generally, we must make our decision within 72 hours of getting your prescribing physician's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get your prescribing physician's supporting statement.

Your physician must submit a statement supporting your coverage determination or exception request. In order to help us make a decision more quickly, you should include supporting medical information from your doctor when you submit your exception request.

What if I have additional questions?

You can call us at: 1-877-391-1105 (seven days a week, 24 hours a day) if you have any additional questions. If you have a hearing or speech impairment, please call us at TTY 711.

IR 420 H5496 ST Program C ENG 11/06/23

ANTICONVULSANTS

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- DILANTIN 30 MG CAPSULE
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION

- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION
- SYMPAZAN 10 MG ORAL FILM
- SYMPAZAN 20 MG ORAL FILM
- SYMPAZAN 5 MG ORAL FILM
- VALTOCO 10 MG/SPRAY (0.1 ML) NASAL SPRAY
- VALTOCO 15 MG/2 SPRAY(7.5MG/0.1ML X2) NASAL SPRAY
- VALTOCO 20 MG/2 SPRAY (10MG/0.1ML X2) NASAL SPRAY
- VALTOCO 5 MG/SPRAY (0.1 ML) NASAL SPRAY

Details

Criteria

Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of a generic formulary anticonvulsant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary anticonvulsant, (2) history of adverse event with a generic formulary anticonvulsant, or (3) generic formulary anticonvulsants are contraindicated.

ANTIDEPRESSANTS

Products Affected

Step 2:

- AUVELITY 45 MG-105 MG TABLET, EXTENDED RELEASE
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET

Details

Criteria Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of any generic formulary antidepressant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary antidepressant, (2) history of adverse event with a generic formulary antidepressant, or (3) generic formulary antidepressants are contraindicated.

ATYPICALS

Products Affected

Step 2:

- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- LYBALVI 10 MG-10 MG TABLET
- LYBALVI 15 MG-10 MG TABLET
- LYBALVI 20 MG-10 MG TABLET
- LYBALVI 5 MG-10 MG TABLET
- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH

- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6)
 CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE
- ZYPREXA RELPREVV 210 MG IM SUSPENSION

Details

Criteria

Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of 2 generic formulary agents in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) diagnosis that is not covered by 2 generic formulary agents, (2) history of inadequate treatment response with 2 generic formulary agents, (3) history of adverse event with 2 generic formulary agents, or (4) 2 generic formulary agents are contraindicated.

RYTARY

Products Affected Step 2:

- RYTARY 23.75 MG-95 MG
- RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE

CAPSULE, EXTENDED RELEASE

- RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE
- RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE

Details

Claim will pay automatically if enrollee has a paid claim for at least a 1	
day supply of generic Carbidopa, Carbidopa/Levodopa, or	
Carbidopa/Levodopa/Entacapone in the past 365 days. Otherwise, Rytary	
requires a step therapy exception request indicating: (1) history of inadequate treatment response with Carbidopa, Carbidopa/Levodopa, or	
Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone, or	
(3) Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone	
is contraindicated.	

INDEX

\mathbf{A}	RYTARY 36.25 MG-145 MG
APTIOM 200 MG TABLET 1	CAPSULE, EXTENDED RELEASE 4
APTIOM 400 MG TABLET 1	RYTARY 48.75 MG-195 MG
APTIOM 600 MG TABLET 1	CAPSULE, EXTENDED RELEASE 4
APTIOM 800 MG TABLET 1	RYTARY 61.25 MG-245 MG
AUVELITY 45 MG-105 MG TABLET,	CAPSULE, EXTENDED RELEASE 4
EXTENDED RELEASE2	\mathbf{S}
D	SECUADO 3.8 MG/24 HOUR
DILANTIN 30 MG CAPSULE 1	TRANSDERMAL 24 HOUR PATCH 3
\mathbf{E}	SECUADO 5.7 MG/24 HOUR
EMSAM 12 MG/24 HR TRANSDERMAL	TRANSDERMAL 24 HOUR PATCH 3
24 HOUR PATCH2	SECUADO 7.6 MG/24 HOUR
EMSAM 6 MG/24 HR TRANSDERMAL	TRANSDERMAL 24 HOUR PATCH 3
24 HOUR PATCH2	SPRITAM 1,000 MG TABLET FOR ORAL
EMSAM 9 MG/24 HR TRANSDERMAL	SUSPENSION1
24 HOUR PATCH2	SPRITAM 250 MG TABLET FOR ORAL
\mathbf{F}	SUSPENSION1
FANAPT 1 MG TABLET 3	SPRITAM 500 MG TABLET FOR ORAL
FANAPT 10 MG TABLET 3	SUSPENSION1
FANAPT 12 MG TABLET 3	SPRITAM 750 MG TABLET FOR ORAL
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6	SUSPENSION1
MG(2) TABLETS IN A DOSE PACK 3	SYMPAZAN 10 MG ORAL FILM 1
FANAPT 2 MG TABLET 3	SYMPAZAN 20 MG ORAL FILM 1
FANAPT 4 MG TABLET 3	SYMPAZAN 5 MG ORAL FILM1
FANAPT 6 MG TABLET 3	T
FANAPT 8 MG TABLET 3	TRINTELLIX 10 MG TABLET 2
FYCOMPA 0.5 MG/ML ORAL	TRINTELLIX 20 MG TABLET 2
SUSPENSION 1	TRINTELLIX 5 MG TABLET2
FYCOMPA 10 MG TABLET 1	\mathbf{V}
FYCOMPA 12 MG TABLET 1	VALTOCO 10 MG/SPRAY (0.1 ML)
FYCOMPA 2 MG TABLET 1	NASAL SPRAY 1
FYCOMPA 4 MG TABLET 1	VALTOCO 15 MG/2
FYCOMPA 6 MG TABLET 1	SPRAY(7.5MG/0.1ML X2) NASAL
FYCOMPA 8 MG TABLET 1	SPRAY1
L	VALTOCO 20 MG/2 SPRAY
LYBALVI 10 MG-10 MG TABLET 3	(10MG/0.1ML X2) NASAL SPRAY 1
LYBALVI 15 MG-10 MG TABLET 3	VALTOCO 5 MG/SPRAY (0.1 ML)
LYBALVI 20 MG-10 MG TABLET 3	NASAL SPRAY 1
LYBALVI 5 MG-10 MG TABLET 3	VERSACLOZ 50 MG/ML ORAL
M	SUSPENSION3
MARPLAN 10 MG TABLET2	VRAYLAR 1.5 MG (1)-3 MG (6)
R	CAPSULES IN A DOSE PACK 3
RYTARY 23.75 MG-95 MG	VRAYLAR 1.5 MG CAPSULE 3
CAPSULE, EXTENDED RELEASE 4	VRAYLAR 3 MG CAPSULE3

VRAYLAR 4.5 MG CAPSULE 3	${f Z}$
VRAYLAR 6 MG CAPSULE 3	ZYPREXA RELPREVV 210 MG IM
	SUSPENSION 3

Formulary ID: 24455 version 6

Last Updated: 08252023 Effective: 01012024